drugset / Trial / NCT06277674
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
Phase 2
Unknown
20 enrolled
Guangzhou University of Traditional Chinese Medicine
Akeso Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study was designed to evaluate the efficacy and safety of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) in combination with pemetrexed and anlotinib for treatment of elderly patients with T790M-negative advanced non-squamous non-small cell lung cancer following resistance to EGFR-TKI.
Timeline
- Start
- 2023-11-02
- Primary completion
- 2024-12
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |